Allison Ballmer is VP at Agilent’s Diagnostics and Genomics Group where she is responsible for strategy and corporate development. Allison recently served as International Business Leader at Roche Molecular Systems where she led all aspects of portfolio and strategy to advance Next Generation Sequencing platforms into the clinic. Allison has enjoyed a 15-year career in Cancer Diagnostics, spanning translational medicine to companion diagnostics. She led Global Marketing and Commercialization for the Swiss-based Molecular Diagnostics arm of Biocartis. She held various Business Development and Commercial leadership roles at Roche and began her career at Ventana Medical Systems in Quality, Regulatory and Operations Management. Allison earned her B.S. in Mechanical Engineering from Virginia Tech, and Strategy and Marketing certifications from London Business School and Cornell University. Allison also serves as a Board Director at Mission Bio, a precision medicine single cell genomics company.
Rapid development of technologies and methods that permit a detailed analysis of the genome and transcriptome of a single cell is offering a window into the extent and nature of genomic and transcriptomic heterogeneity which occurs in both normal development and disease. Single-cell approaches stand poised to revolutionize our capacity to understand the scale of genomic, epigenomic, and transcriptomic diversity that occurs during the lifetime of an individual organism. This session will review the major technological and biological breakthroughs achieved, describe the remaining challenges to overcome, and provide a glimpse into the promise of recent and future developments.